

# Willi Sauerbrei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5646422/publications.pdf>

Version: 2024-02-01

136  
papers

15,639  
citations

50276

46  
h-index

19190

118  
g-index

156  
all docs

156  
docs citations

156  
times ranked

25282  
citing authors

#	ARTICLE	IF	CITATIONS
1	Review of guidance papers on regression modeling in statistical series of medical journals. PLoS ONE, 2022, 17, e0262918.	2.5	10
2	Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials. BMC Medical Research Methodology, 2022, 22, 98.	3.1	3
3	Structured reporting to improve transparency of analyses in prognostic marker studies. BMC Medicine, 2022, 20, 184.	5.5	6
4	Doug Altman: Driving critical appraisal and improvements in the quality of methodological and medical research. Biometrical Journal, 2021, 63, 226-246.	1.0	6
5	Facilitating harmonized data quality assessments. A data quality framework for observational health research data collections with software implementations in R. BMC Medical Research Methodology, 2021, 21, 63.	3.1	47
6	Combining clinical and molecular data in regression prediction models: insights from a simulation study. Briefings in Bioinformatics, 2020, 21, 1904-1919.	6.5	11
7	Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Cmaj, 2020, 192, E901-E906.	2.0	271
8	Introduction to statistical simulations in health research. BMJ Open, 2020, 10, e039921.	1.9	24
9	Statistical models for complex data in clinical and epidemiological research. Biometrical Journal, 2020, 62, 528-531.	1.0	0
10	State of the art in selection of variables and functional forms in multivariable analysisâ€”outstanding issues. Diagnostic and Prognostic Research, 2020, 4, 3.	1.8	114
11	Use of Resampling Procedures to Investigate Issues of Model Building and Its Stability. , 2020, , 1-24.		1
12	Systematic review of education and practical guidance on regression modeling for medical researchers who lack a strong statistical background: Study protocol. PLoS ONE, 2020, 15, e0241427.	2.5	3
13	Exploration of the variability of variable selection based on distances between bootstrap sample results. Advances in Data Analysis and Classification, 2019, 13, 933-963.	1.4	8
14	A plea for taking all available clinical information into account when assessing the predictive value of omics data. BMC Medical Research Methodology, 2019, 19, 162.	3.1	10
15	A review of spline function procedures in R. BMC Medical Research Methodology, 2019, 19, 46.	3.1	288
16	Prevention of Cervical Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 160-176.	1.8	26
17	Modeling exposures with a spike at zero: simulation study and practical application to survival data. Biostatistics and Epidemiology, 2019, 3, 23-37.	0.4	6
18	Meta-analysis of non-linear exposureâ€“outcome relationships using individual participant data: A comparison of two methods. Statistics in Medicine, 2019, 38, 326-338.	1.6	22

#	ARTICLE	IF	CITATIONS
19	Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 1360-1369.	6.3	14
20	Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'. British Journal of Cancer, 2018, 118, 1152-1153.	6.4	3
21	On the necessity and design of studies comparing statistical methods. Biometrical Journal, 2018, 60, 216-218.	1.0	66
22	Handling co-dependence issues in resampling-based variable selection procedures: a simulation study. Journal of Statistical Computation and Simulation, 2018, 88, 28-55.	1.2	4
23	Overinterpretation and misreporting of prognostic factor studies in oncology: a systematic review. British Journal of Cancer, 2018, 119, 1288-1296.	6.4	25
24	Education for biometry in practice. Biometrical Journal, 2018, 60, 1021-1021.	1.0	0
25	Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. Journal of the National Cancer Institute, 2018, 110, 803-811.	6.3	332
26	Importance of the distinction between quality of methodology and quality of reporting. Hpb, 2017, 19, 649-650.	0.3	4
27	Detection of influential points as a byproduct of resampling-based variable selection procedures. Computational Statistics and Data Analysis, 2017, 116, 19-31.	1.2	4
28	Modeling Variables With a Spike at Zero: Examples and Practical Recommendations. American Journal of Epidemiology, 2017, 185, 650-660.	3.4	19
29	Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles. PLoS ONE, 2017, 12, e0178531.	2.5	31
30	On Fishing for Significance and Statistician's Degree of Freedom in the Era of Big Molecular Data. , 2017, , 155-170.		4
31	Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS. BMJ Open, 2016, 6, e011148.	1.9	13
32	Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example. BMJ Open, 2016, 6, e009972.	1.9	7
33	Subsampling Versus Bootstrapping in Resampling-Based Model Selection for Multivariable Regression. Biometrics, 2016, 72, 272-280.	1.4	70
34	Modeling continuous covariates with a 'spike' at zero: Bivariate approaches. Biometrical Journal, 2016, 58, 783-796.	1.0	6
35	Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example. PLoS ONE, 2016, 11, e0149977.	2.5	17
36	mfp: Extension of mfp using the ACD covariate transformation for enhanced parametric multivariable modeling. The Stata Journal, 2016, 16, 72-87.	2.2	4

#	ARTICLE	IF	CITATIONS
37	Dose-response modelling for bivariate covariates with and without a spike at zero: theory and application to binary outcomes. <i>Statistica Neerlandica</i> , 2015, 69, 374-398.	1.6	4
38	On stability issues in deriving multivariable regression models. <i>Biometrical Journal</i> , 2015, 57, 531-555.	1.0	43
39	Investigating the prediction ability of survival models based on both clinical and omics data: two case studies. <i>Statistics in Medicine</i> , 2014, 33, 5310-5329.	1.6	36
40	STRengthening Analytical Thinking for Observational Studies: the STRATOS initiative. <i>Statistics in Medicine</i> , 2014, 33, 5413-5432.	1.6	94
41	Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation - protocol of the ICEM study. <i>Systematic Reviews</i> , 2014, 3, 46.	5.3	5
42	Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis. <i>Statistics in Medicine</i> , 2014, 33, 4695-4708.	1.6	26
43	Comparison between splines and fractional polynomials for multivariable model building with continuous covariates: a simulation study with continuous response. <i>Statistics in Medicine</i> , 2013, 32, 2262-2277.	1.6	83
44	Cross-Validation, Shrinkage and Variable Selection in Linear Regression Revisited. <i>Open Journal of Statistics</i> , 2013, 03, 79-102.	0.7	32
45	Prognosis research strategy (PROGRESS) 4: Stratified medicine research. <i>BMJ, The</i> , 2013, 346, e5793-e5793.	6.0	367
46	Exaggeration of the Prognostic Effect of Mammostrat: A Consequence of Poor Reporting?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2760-2761.	1.6	1
47	Interaction of treatment with a continuous variable: simulation study of significance level for several methods of analysis. <i>Statistics in Medicine</i> , 2013, 32, 3788-3803.	1.6	30
48	Treatment of Primary Breast Cancer at the Surgical Unit of the Charit� 1984-1998. <i>Oncology Research and Treatment</i> , 2013, 36, 727-736.	1.2	2
49	Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration. <i>PLoS Medicine</i> , 2012, 9, e1001216.	8.4	650
50	Prognostic Factor Studies. , 2012, , 415-470.		9
51	Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. <i>BMC Medicine</i> , 2012, 10, 51.	5.5	297
52	Individual participant data meta-analysis of prognostic factor studies: state of the art?. <i>BMC Medical Research Methodology</i> , 2012, 12, 56.	3.1	69
53	Analysing covariates with spike at zero: A modified FP procedure and conceptual issues. <i>Biometrical Journal</i> , 2012, 54, 686-700.	1.0	16
54	Comments on "Performance of using multiple stepwise algorithms for variable selection" by Ryan E. Wiegand, <i>Statistics in Medicine</i> 2010; 29:1647-1659. <i>Statistics in Medicine</i> , 2011, 30, 892-894.	1.6	1

#	ARTICLE	IF	CITATIONS
55	A new strategy for meta-analysis of continuous covariates in observational studies. <i>Statistics in Medicine</i> , 2011, 30, 3341-3360.	1.6	33
56	Comparison of procedures to assess non-linear and time-varying effects in multivariable models for survival data. <i>Biometrical Journal</i> , 2011, 53, 308-331.	1.0	27
57	Use of pretransformation to cope with extreme values in important candidate features. <i>Biometrical Journal</i> , 2011, 53, 673-688.	1.0	3
58	Stability Investigations of Multivariable Regression Models Derived from Low- and High-Dimensional Data. <i>Journal of Biopharmaceutical Statistics</i> , 2011, 21, 1206-1231.	0.8	104
59	Added predictive value of high-throughput molecular data to clinical data and its validation. <i>Briefings in Bioinformatics</i> , 2011, 12, 215-229.	6.5	46
60	Information from CTC measurements for metastatic breast cancer prognosis—we should do more than selecting an “optimal cut point”. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 219-220.	2.5	12
61	Modelling continuous exposures with a “spike” at zero: A new procedure based on fractional polynomials. <i>Statistics in Medicine</i> , 2010, 29, 1219-1227.	1.6	34
62	Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. <i>British Journal of Cancer</i> , 2010, 102, 173-180.	6.4	112
63	An Experimental Evaluation of Boosting Methods for Classification. <i>Methods of Information in Medicine</i> , 2010, 49, 219-229.	1.2	13
64	Two Techniques for Investigating Interactions between Treatment and Continuous Covariates in Clinical Trials. <i>The Stata Journal</i> , 2009, 9, 230-251.	2.2	49
65	Bootstrap Assessment of the Stability of Multivariable Models. <i>The Stata Journal</i> , 2009, 9, 547-570.	2.2	51
66	Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. <i>British Journal of Cancer</i> , 2009, 100, 1219-1229.	6.4	127
67	Stability analysis of an additive spline model for respiratory health data by using knot removal. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2009, 58, 577-600.	1.0	7
68	Investigation about a screening step in model selection. <i>Statistics and Computing</i> , 2008, 18, 195-208.	1.5	16
69	On properties of predictors derived with a two-step bootstrap model averaging approach—A simulation study in the linear regression model. <i>Computational Statistics and Data Analysis</i> , 2008, 52, 2778-2793.	1.2	22
70	Increasing the usefulness of additive spline models by knot removal. <i>Computational Statistics and Data Analysis</i> , 2008, 52, 5305-5318.	1.2	3
71	Interactions Between Treatment and Continuous Covariates: A Step Toward Individualizing Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 1397-1399.	1.6	44
72	Multivariable Modeling with Cubic Regression Splines: A Principled Approach. <i>The Stata Journal</i> , 2007, 7, 45-70.	2.2	177

#	ARTICLE	IF	CITATIONS
73	A New Proposal for Multivariable Modelling of Time-Varying Effects in Survival Data Based on Fractional Polynomial Time-Transformation. Biometrical Journal, 2007, 49, 453-473.	1.0	84
74	Improving the robustness of fractional polynomial models by preliminary covariate transformation: A pragmatic approach. Computational Statistics and Data Analysis, 2007, 51, 4240-4253.	1.2	40
75	Detecting an interaction between treatment and a continuous covariate: A comparison of two approaches. Computational Statistics and Data Analysis, 2007, 51, 4054-4063.	1.2	29
76	Modelling to extract more information from clinical trials data: On some roles for the bootstrap. Statistics in Medicine, 2007, 26, 4989-5001.	1.6	18
77	Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Statistics in Medicine, 2007, 26, 5512-5528.	1.6	876
78	Evidence-Based Assessment and Application of Prognostic Markers: The Long Way from Single Studies to Meta-Analysis. Communications in Statistics - Theory and Methods, 2006, 35, 1333-1342.	1.0	26
79	Dichotomizing continuous predictors in multiple regression: a bad idea. Statistics in Medicine, 2006, 25, 127-141.	1.6	1,711
80	Multivariable regression model building by using fractional polynomials: Description of SAS, STATA and R programs. Computational Statistics and Data Analysis, 2006, 50, 3464-3485.	1.2	291
81	REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Research and Treatment, 2006, 100, 229-235.	2.5	666
82	RESPONSE: Re: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). Journal of the National Cancer Institute, 2005, 97, 1855-1856.	6.3	6
83	Identification of Clinically Useful Cancer Prognostic Factors: What Are We Missing?. Journal of the National Cancer Institute, 2005, 97, 1023-1025.	6.3	76
84	The practical utility of incorporating model selection uncertainty into prognostic models for survival data. Statistical Modelling, 2005, 5, 95-118.	1.1	30
85	Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). Journal of the National Cancer Institute, 2005, 97, 1180-1184.	6.3	1,323
86	Prognostic Factor Studies. , 2005, , 289-333.		3
87	Prognostic Factors. , 2004, 62, 184-200.		26
88	Is treatment with interferon- $\alpha$ effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. British Journal of Cancer, 2004, 90, 794-799.	6.4	32
89	Confidence intervals for the effect of a prognostic factor after selection of an "optimal" cutpoint. Statistics in Medicine, 2004, 23, 1701-1713.	1.6	93
90	A new measure of prognostic separation in survival data. Statistics in Medicine, 2004, 23, 723-748.	1.6	371

#	ARTICLE	IF	CITATIONS
91	A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. <i>Statistics in Medicine</i> , 2004, 23, 2509-2525.	1.6	234
92	Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. <i>Oncology Reports</i> , 2004, 11, 905-10.	2.6	15
93	Multivariate Analysis of Prognostic Factors in Patients with Glioblastoma. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 8-15.	2.0	86
94	Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). <i>Osteoporosis International</i> , 2003, 14, 1001-1006.	3.1	105
95	Tumor stage and early mortality for surgical resections in lung cancer. <i>Langenbeck's Archives of Surgery</i> , 2003, 388, 116-121.	1.9	10
96	Stability of multivariable fractional polynomial models with selection of variables and transformations: a bootstrap investigation. <i>Statistics in Medicine</i> , 2003, 22, 639-659.	1.6	103
97	Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Methotrexate + Fluorouracil—Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 4510-4516.	1.6	61
98	Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 4628-4635.	1.6	323
99	Long-Term Follow-Up of Patients in Four Prospective Studies of the German Breast Cancer Study Group (GBSG): A Summary of Key Results. <i>Oncology Research and Treatment</i> , 2002, 25, 143-150.	1.2	9
100	Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. <i>Cancer Gene Therapy</i> , 2002, 9, 478-481.	4.6	11
101	Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. <i>British Journal of Cancer</i> , 2002, 86, 1705-1714.	6.4	59
102	On alcohol consumption and all-cause mortality. <i>Journal of Clinical Epidemiology</i> , 2001, 54, 537-538.	5.0	6
103	Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. , 2000, 86, 408-415.		11
104	Sample size considerations for the evaluation of prognostic factors in survival analysis. , 2000, 19, 441-452.		89
105	Role of Isolated Locoregional Recurrence of Breast Cancer: Results of Four Prospective Studies. <i>Journal of Clinical Oncology</i> , 2000, 18, 1696-1708.	1.6	138
106	Randomized 2 Å— 2 Trial Evaluating Hormonal Treatment and the Duration of Chemotherapy in Node-Positive Breast Cancer Patients: An Update Based on 10 Yearsâ€™ Follow-Up. <i>Journal of Clinical Oncology</i> , 2000, 18, 94-94.	1.6	34
107	The use of fractional polynomials to model continuous risk variables in epidemiology. <i>International Journal of Epidemiology</i> , 1999, 28, 964-974.	1.9	966
108	The Use of Resampling Methods to Simplify Regression Models in Medical Statistics. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 1999, 48, 313-329.	1.0	216

#	ARTICLE	IF	CITATIONS
109	Modelling the effects of standard prognostic factors in node-positive breast cancer. British Journal of Cancer, 1999, 79, 1752-1760.	6.4	83
110	Assessment and comparison of prognostic classification schemes for survival data. , 1999, 18, 2529-2545.		584
111	Traditional reviews, meta-analyses and pooled analyses in epidemiology. International Journal of Epidemiology, 1999, 28, 1-9.	1.9	486
112	Assessment and comparison of prognostic classification schemes for survival data. Statistics in Medicine, 1999, 18, 2529-2545.	1.6	1
113	A note on estimating local recurrence rates in clinical trials on the treatment of breast cancer. Breast Cancer Research and Treatment, 1998, 49, 87-91.	2.5	14
114	Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Research and Treatment, 1998, 48, 191-192.	2.5	0
115	Differentiation of benign and malignant breast tumors by logistic regression and a classification tree using Doppler flow signals. Methods of Information in Medicine, 1998, 37, 226-34.	1.2	8
116	Color Doppler and Duplex Flow Analysis for Classification of Breast Lesions. Gynecologic Oncology, 1997, 64, 392-403.	1.4	58
117	Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease. Gynecologic Oncology, 1997, 66, 75-84.	1.4	25
118	Diagnostic formula for the differentiation of adnexal tumors by transvaginal sonography. Obstetrics and Gynecology, 1997, 89, 428-433.	2.4	15
119	The Importance of Basic Statistical Principles for the Interpretation of Epidemiological Data. Oncology Research and Treatment, 1997, 20, 455-460.	1.2	2
120	Validation of existing and development of new prognostic classification schemes in node negative breast cancer. Breast Cancer Research and Treatment, 1997, 42, 149-163.	2.5	66
121	Resampling and cross-validation techniques: a tool to reduce bias caused by model building?. , 1997, 16, 2813-2827.		118
122	Development and validation of diagnostic scores for atopic dermatitis incorporating criteria of data quality and practical usefulness. Journal of Clinical Epidemiology, 1996, 49, 1031-1038.	5.0	169
123	Classification of Adnexal Tumors by Transvaginal Color Doppler. Gynecologic Oncology, 1996, 61, 354-363.	1.4	24
124	Therapy of small breast cancer - four-year results of a prospective non-randomized study. Breast Cancer Research and Treatment, 1995, 34, 1-13.	2.5	22
125	Effect of timing of surgery during the menstrual cycle of premenopausal breast cancer patients. Breast Cancer Research and Treatment, 1995, 34, 279-287.	2.5	17
126	Prognostic Value of DNA Ploidy and S-Phase Fraction in Stage I Endometrial Carcinoma. Gynecologic Oncology, 1995, 58, 149-156.	1.4	36



#	ARTICLE	IF	CITATIONS
127	Timing of breast cancer surgery – some arguments that there is no effect. Annals of Oncology, 1994, 5, 25-27.	1.2	12
128	Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group.. Journal of Clinical Oncology, 1994, 12, 2086-2093.	1.6	166
129	Cellular DNA content and survival in advanced ovarian carcinoma. Cancer, 1994, 74, 2509-2515.	4.1	37
130	Human papillomavirus DNA in cervical carcinoma – correlation with clinical data and influence on prognosis. International Journal of Cancer, 1994, 59, 322-326.	5.1	40
131	Color Doppler flow criteria of breast lesions. Ultrasound in Medicine and Biology, 1994, 20, 849-858.	1.5	58
132	Influence of model-building strategies on the results of a case-control study. Statistics in Medicine, 1993, 12, 1325-1338.	1.6	29
133	The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Research and Treatment, 1993, 25, 235-245.	2.5	48
134	Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects. Gynecologic Oncology, 1992, 47, 317-322.	1.4	64
135	A bootstrap resampling procedure for model building: Application to the cox regression model. Statistics in Medicine, 1992, 11, 2093-2109.	1.6	537
136	CA-125 serum concentrations during the menstrual cycle. Fertility and Sterility, 1988, 50, 223-227.	1.0	42